303-95-7

Basic information

• Product Name: ubiquinone 7
• Synonyms: ubiquinone 7;2,5-Cyclohexadiene-1,4-dione, 2-((2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-heptamethyl-2,6,10,14,18,22,26-octacosaheptaenyl)-5,6-dimethoxy-3-methyl-;2,5-Cyclohexadiene-1,4-dione, 2-(3,7,11,15,19,23,27-heptamethyl-2,6,10,14,18,22,26-octacosaheptenyl)-5,6-dimethoxy-3-methyl-, (all-E)-;Brn 2406878;Coenzyme Q7 (6ci);Coq7;Ubiquinone 35;Ubiquinone Q7
• CAS NO: 303-95-7
• Molecular Formula: C₄₄H₆₆O₄
• Molecular Weight: 659.001
• Product Categories: Fatty Acid Derivatives & Lipids;Glycerols;Glycerols, Fatty Acid Derivatives & Lipids
• Mol File: 303-95-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C
• CAS DataBase Reference: ubiquinone 7(CAS DataBase Reference)
• NIST Chemistry Reference: ubiquinone 7(303-95-7)
• EPA Substance Registry System: ubiquinone 7(303-95-7)

Safety Data

• Hazardous Substances Data: 303-95-7(Hazardous Substances Data)

Usage

Description

Ubiquinone 7, also known as Coenzyme Q7, is an isoprenoid quinone compound characterized by a 2,3-dimethoxy-5-methylbenzoquinone nucleus and a side chain of seven isoprenoid units. It plays a crucial role in cellular energy production and has been found to have various health benefits.

Uses

Used in Pharmaceutical Industry:
Ubiquinone 7 is used as a therapeutic agent for diabetics, as it significantly reduces blood sugar and ketone bodies, helping to manage and alleviate symptoms of diabetes.
Used in Dental Industry:
Ubiquinone 7 is used as a treatment for periodontal disease, as it has been shown to decrease high blood citrate levels in humans with this condition, potentially improving oral health and reducing the severity of the disease.
Used in Muscular Dystrophy Treatment:
Ubiquinone 7 is used as a viable therapeutic agent for muscular dystrophy, a group of genetic disorders characterized by progressive muscle degeneration and weakness. Its role in cellular energy production may contribute to improved muscle function and overall health in patients with this condition.

InChI:InChI=1/C44H66O4/c1-32(2)18-12-19-33(3)20-13-21-34(4)22-14-23-35(5)24-15-25-36(6)26-16-27-37(7)28-17-29-38(8)30-31-40-39(9)41(45)43(47-10)44(48-11)42(40)46/h18,20,22,24,26,28,30H,12-17,19,21,23,25,27,29,31H2,1-11H3/b33-20+,34-22+,35-24+,36-26+,37-28+,38-30+

Upstream product

• 605-94-7 2,3-Dimethoxy-5-methyl-1,4-benzoquinone 
• 74610-05-2 ((2E,6E,10E,14E,18E,22E)-3,7,11,15,19,23,27-Heptamethyl-octacosa-2,6,10,14,18,22,26-heptaenyl)-trimethyl-stannane 
• 75-24-1 trimethylaluminum 
• 202843-56-9 2-chloromethyl-5,6-dimethoxy-3-methyl-[1,4]benzoquinone 
• 257885-58-8 (5E,9E,13E,17E,21E)-6,10,14,18,22,26-Hexamethyl-heptacosa-5,9,13,17,21,25-hexaen-1-yne 
• 26394-25-2 (E)-4-chloro-2-methylbut-2-enal 
• 3330-23-2 2-hydroxy-2-methyl-3-butenal dimethyl acetal 
• 56904-88-2 trans-3-hydroxymethyl-2-butenyl chloride 
• 68799-82-6 1-chloro-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraene 
• 129746-03-8 (E)-4-(Tetrahydropyran-2-yloxy)-3-methylbut-2-enylchloride 
• 68690-47-1 1-methyl-4-{[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]sulfonyl}benzene 
• 1838-94-4 isoprene epoxide 
• 257885-44-2 E-2-methyl-7-trimethylsilyl-2-buten-6-yn-1-al 
• 257885-47-5 E-1-chloro-2-methyl-7-trimethylsilyl-2-buten-6-yne 

Downstream Products

• 484-59-3 reduced coenzyme Q₇ 
• 69060-01-1 Ubichinol-7-dibenzylether 
• 24904-69-6 trans-γ-Methoxy-isoubichinon-7 
• 24904-71-0 trans-γ-Aethoxy-isoubichinon-7 
• 24989-52-4 trans-γ-Hydroxy-isoubichinon-7 
• 28111-39-9 trans-γ-Hydroperoxy-isoubichinon-7 
• 81112-33-6 Ubihydrochinon-⁽³⁵⁾-diacetat 
• 69060-02-2 (6E,10E,14E,18E,22E,26E)-28-(2,5-Bis-benzyloxy-3,4-dimethoxy-6-methyl-phenyl)-3-bromo-2,6,10,14,18,22,26-heptamethyl-octacosa-6,10,14,18,22,26-hexaen-2-ol 
• 24904-66-3 γ-Methoxy-perhydro-ubichinon-7 
• 24904-67-4 γ-Aethoxy-perhydro-ubichinon-7 
• 74075-00-6 ubiquinol-8 
• 75426-26-5 ubiquinol 
• 5677-54-3 ubiquinone-9 

Relevant articles and documents

A convergent approach to coenzyme Q

Syntheses of coenzyme Q3-8 are described, as well as related systems such as plastoquinone-5. Preparation of the higher homologues of the ubiquinones relies on two new conjunctive reagents, or "linchpins", each of which ultimately corresponds to two or three prenyl units. These allow for attachment of a polyprenyl halide at one end, followed by a Ni(0)-catalyzed cross-coupling at the other terminus with a chloromethylated p-quinone.

PHOTOCHEMICAL REACTION OF UBIQUINONE (35). I. FORMATION OF

-